

# Accepted Manuscript

Trends and economics drivers for United States naloxone pricing,  
January 2006 to February 2017

Matthew Rosenberg, Grace Chai, Shekhar Mehta, Andreas Schick



PII: S0306-4603(18)30469-6  
DOI: doi:[10.1016/j.addbeh.2018.05.006](https://doi.org/10.1016/j.addbeh.2018.05.006)  
Reference: AB 5559  
To appear in: *Addictive Behaviors*  
Received date: 30 August 2017  
Revised date: 2 May 2018  
Accepted date: 7 May 2018

Please cite this article as: Matthew Rosenberg, Grace Chai, Shekhar Mehta, Andreas Schick , Trends and economics drivers for United States naloxone pricing, January 2006 to February 2017. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Ab(2017), doi:[10.1016/j.addbeh.2018.05.006](https://doi.org/10.1016/j.addbeh.2018.05.006)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Trends and Economics Drivers for United States Naloxone Pricing, January 2006 to February 2017

Matthew Rosenberg, MSPPM<sup>a</sup>, Grace Chai, PharmD<sup>a</sup>, Shekhar Mehta, PharmD, MS<sup>a</sup>, Andreas Schick, PhD<sup>a</sup>,

Matthew Rosenberg, MSPPM<sup>a</sup>  
Economics Staff, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research  
U.S. Food and Drug Administration

Grace Chai, PharmD<sup>a</sup>  
LCDR, USPHS  
Division of Epidemiology II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research  
U.S. Food and Drug Administration

Shekhar Mehta, PharmD, MS<sup>a</sup>  
Division of Epidemiology II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research  
U.S. Food and Drug Administration

Andreas Schick, PhD<sup>a</sup>  
Economics Staff, Office of Program and Strategic Analysis, Office of Strategic Programs, Center for Drug Evaluation and Research  
U.S. Food and Drug Administration

<sup>a</sup>Food and Drug Administration  
10903 New Hampshire Avenue  
Silver Spring, MD 20993  
United States of America  
E-Mail Addresses: [matthew.rosenberg@fda.hhs.gov](mailto:matthew.rosenberg@fda.hhs.gov); [grace.chai@fda.hhs.gov](mailto:grace.chai@fda.hhs.gov);  
[shekhar.mehta@fda.hhs.gov](mailto:shekhar.mehta@fda.hhs.gov); [andreas.schick@fda.hhs.gov](mailto:andreas.schick@fda.hhs.gov)

Corresponding Author:

Matthew Rosenberg  
10903 New Hampshire Avenue  
Building 51, Room 1166  
Silver Spring, MD 20993  
[Matthew.Rosenberg@fda.hhs.gov](mailto:Matthew.Rosenberg@fda.hhs.gov)  
(240)-402-5097

Download English Version:

<https://daneshyari.com/en/article/7258830>

Download Persian Version:

<https://daneshyari.com/article/7258830>

[Daneshyari.com](https://daneshyari.com)